Galecto Biotech receives further funding

Wednesday 2 May 2012

Galecto Biotech AB has expanded its investor syndicate and raised a further €5 million to support the development of its small-molecule modulators of the galectin family of proteins. Total capital raised thus far is €10 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden